your ad here


    Eight Rules for '08
    by Bennet Kelley
    Five Words That Change Lives
    by Missy Comley Beattie
    Top-Down Versus Bottom-Up Impeachment
    by John R Moffett
    Top Ten Reasons Why Activists Shouldn't Be "Too Radical"
    by Mickey Z.
    "The Ballad of Sarasota" captures Voters' Angst
    by Mary Ann Gould
    It Really Is This Simple - Bloggers Are About The Real World
    by Dave Johnson
    Selling Son of Star Wars Missile Defense To Europe Threatens New Cold War
    by Ron Fullwood
    Call Me Paranoid. Pentagon Creating Red State Officer Corps
    by Rob Kall
    Our National Hopes and Dreams in Images
    by David Swanson
    Democratic Presidential Candidates Help me Make up my Mind!
    by Steven Leser
    Why Congress Must Reauthorize the Use of the Constitution
    by David Swanson
    Can Voters Opposed to the Iraq War Trust Hillary Clinton?
    by Kevin Zeese
    U.S. Makes Overture to Thailand: We need You as an Ally; A Democratic Ally
    by John Carey
    I Sat Down to Write of the End of America
    by Bruce Morris
    by Professor Emeritus Peter Bagnolo
    by Diane Marie
    Reasons to Doubt the Official Story about the 9/11 Attacks
    by Andrew Mills
    Newspapers Puzzled About Their Failings: part 1
    by thomas bonsell
    War Wounds of The Mind Part IV: A Warning About Troops Returning from Iraq and Afghanistan
    by John Carey
    No One Here Gets Out Alive: Americans' refusal to look in the mirror presages our own demise
    by Dan Welch
    Why not state the plain facts about the genocide in Iraq?
    by winston winston
    Merck Can't Get Its Way, But For How Long?
    by Sandy Sand


    Subject(s): ; ; ; ; ; ; ; ; ;
    Local Area(s): ; ; ; ; ; ; ; ; ; ;
    Add to My Group
    February 22, 2007 at 01:25:45

    Off-Label Sales of SSRIs Leads To More Litigation

    by Evelyn Pringle

    Tell A Friend

    Off-label prescribing of prescription drugs overall is widespread in the US, but nowhere is it more prevalent than with the antidepressant drugs known as selective serotonin reuptake inhibitors. A study in the June 2005, Journal of Clinical Psychiatry, found that 75% of the prescriptions written for SSRIs were for treatments not approved by the FDA.

    The study's lead author, Dr Hua Chen, an assistant professor at the University of Houston, said the findings reveal a significant gap in the US drug safety system and off-label prescribing regularly exposes consumers to drugs that are untested for their condition.

    The FDA approves drugs for uses that have been tested and proven to be safe and effective. The term off-label means prescribing a drug for a use not approved or for a different patient population, such as children instead of adults, or at a different dose or duration than was determined by the FDA to have a favorable risk-benefit ratio.

    While doctors may legally prescribe a drug for an off-label use, drug makers are barred from promoting a drug for unapproved uses, but it is a widely known that it occurs on a regular basis. For instance, SSRIs are still being prescribed off-label for a multitude of unapproved conditions to patient groups that includes children as young as toddlers, the elderly, and pregnant women.

    Over the past 20 years, SSRIs have been prescribed off-label for everything from anxiety to pain, insomnia, shyness, menstrual discomfort, dementia, restless leg syndrome, and a host of other invented disorders sold to the public with the help of industry funded front groups and PR firms.

    Possibly with the exception of Vioxx, in the end SSRIs will probably hold the title for not only the most side effects but also for the most lawsuits filed against SSRI makers due to their conduct of concealing studies that identified serous adverse events while at the same time overstating their efficacy, in the name of profits.

    This class of drugs has now been found to be associated with suicidality, extreme violence and homicide, several life-threatening birth defects, abnormal uterine or gastrointestinal bleeding, a decrease in bone mineral density, fertility problems, sexual dysfunction, and a severe withdrawal syndrome.

    In large part because the SSRI makers have been ripping off public health care programs by billing the government for the vast majority of off-label prescriptions, Federal and state law enforcement agencies are zeroing in on the drug companies and the doctors who are writing the off-label prescriptions as a result of kickbacks of some form or another.

    The various illegal marketing schemes are taking their toll on public health care programs. According to the US Department of Health and Human Services, in 2005, Medicaid paid $41 billion for prescription drugs, well over 4 times the $8.9 billion spent in 1994.

    Several Congressional Committees are currently investigating the off-label promotion of drugs by the pharmaceutical industry. While testifying at a US House Committee on Oversight and Government Reform on February 9, 2007, Lewis Morris, Chief Counsel at the Department of Health and Human Services' Office of Inspector General, informed members of Congress about the adverse effects of prescribing drugs for unapproved uses.

    "Off-label promotion," he said, "may lead physicians to prescribe a product for a non-approved use based on false, misleading, or erroneous information to the medical detriment of their patients."

    "In addition," Mr Morris continued, "off-label promotion fundamentally circumvents the FDA drug approval process, on which Americans rely to evaluate the safety and efficacy of pharmaceutical products."

    Mr Morris warned that physicians may be under the wrong impression that they can demand "kickbacks from drug companies with impunity," because in the past prosecutors have focused on the drug makers paying the kickbacks.

    But in cracking down on doctors, Mr Morris told the Committee that the OIG plans to use its authority to impose monetary penalties and the exclusion of doctors from public health care programs who are found to be accepting kickbacks.

    Ronald Tenpas, associate deputy attorney general in the Department of Justice, testified about the harm caused by the corruption of doctors on the public as a whole. "By inducing physicians to prescribe for uses that have not been approved," he said, "either by promoting compromised "science" or offering financial incentives, manufacturers are subverting a healthcare system that necessarily relies on the objective medical judgment of practitioners, and their actions may also harm the public health."

    "It is clear," Mr Tenpas said, "from our experience that drug company violations of the law are causing government health-care programs to pay too much for prescription drugs."

    "We are not seeing isolated instances of misconduct," he told the panel, "but repeated practices within the industry that have resulted in significant loses to federal health-care programs."

    The majority of lawsuits against drug companies alleging illegal marketing schemes aimed at public health care programs were filed under the provisions of the Federal False Claims Act, which allows persons who find evidence of fraud to bring suit on behalf of the government and collect a percentage of the amount recovered.

    These whistleblower cases are first filed under seal until the DOJ investigates the charges and decides whether to intervene. Over the past six years, the government has recovered close to $4 billion in 16 cases involving Medicaid with Pfizer paying the highest penalty of $430 million for the off-label marketing of the epilepsy drug Neurontin.

    The list of side effects associated with SSRIs that have surfaced over the past 2 decades continues to grow every year. But ironically, the drug companies have been so adept at keeping negative information about SSRIs hidden that most of the side effects only come to light as a result of litigation.

    All SSRI makers have lawsuits pending involving a variety of adverse events. For example, in June 14, 2006, SEC filings, Lexapro and Celexa maker, Forest Laboratories says the company is a named defendant in approximately 25 active lawsuits, with most alleging that Lexapro or Celexa contributed to persons committing or attempting suicide.

    In addition, Forest is under investigation by the US Attorney's Office for the District of Massachusetts to determine whether Forest committed civil and criminal violations of the Anti-Kickback laws related to the off-label marketing of Celexa and Lexapro.

    However, legal experts say drug companies view lawsuits as a minor problem and chock them up to the cost of doing business. For instance, what are 25 lawsuits to Forest, when Celexa and Lexapro, accounted for 68% of the company's sales last year. In fact, Lexapro revenues were 16% higher in the 4th quarter at $464,100,000, compared to $399,381,000 in the same quarter the year before.

    Raymond Badyna has a Lexapro-induced suicide lawsuit pending in New Jersey filed on behalf of his deceased son, Ray Badyna's estate, by attorneys, Derek Braslow and Harris Pogust, of the Pogust & Braslow, LLC firm, in Conshohocken, Pennsylvania.

    Ray's suicide was totally unexpected. His friends and family members say there is no logical explanation for it other then the effect of Lexapro. On October 7, 2003, Ray received great news that for the second year in a row, his job performance for the year had qualified him to receive the, "Countrywide Circle of Excellence Award."

    And yet two days later at age 32, he committed suicide. "Had Ray or his physician known of the increased risk of suicide and suicidal ideation from Lexapro," the lawsuit states, "Ray would have never taken the drug."

    Although Ray said nothing to his family that would indicate he planned to kill himself, after his death, it became known that Ray had expressed thoughts about harming himself to other people. In one conversation with a friend, Ray complained that Lexapro was making him "feel weird" and he "had very strange thoughts running through his mind."

    Mr Braslow explains that SSRIs are designed to alter serotonin levels in the brain. "For years," he reports, "it has been known that serotonin functioning is directly related to aggression and violence, both directed at oneself and at others."

    "Unfortunately," he states, "there is a vulnerable population of patients who are at an increased risk of violence and suicide as a result of taking Celexa, Lexapro and other SSRI drugs."

    According to Attorney Pogust, the SSRI manufacturers have known about this population of high-risk patients for many years. "And, yet," he says, "these companies have failed to conduct any tests to determine the frequency of this phenomenon or to develop ways of identifying and protecting those patients who are in the high risk group."

    As far back as November 1991, Dr John Mann, who now regularly serves as an expert witness for SSRI makers, coauthored an article titled, "The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy," in the Archives of General Psychiatry in which he discussed the phenomenon of "iatrogenic suicide," also known as physician-induced suicide, and warned that there may be a "small vulnerable subpopulation" of patients for whom SSRIs pose a risk of suicide or violence.

    In the paper, Dr Mann took it a step further and suggested protocols for studies that could be used to test this hypothesis and the drug companies deliberately did not conduct the research because they knew it would confirm Dr Mann's findings and a warning of such serious adverse events on the labels of SSRIs would have had a negative impact on sales.

    "But worst of all," Mr Braslow says, "is that the SSRI manufacturers failed to warn prescribing physicians about the suicide risk or to instruct them on ways to reduce the risk."

    Lexapro did not help Ray's condition and in 20/20 hindsight, his family recalls that after he began taking the drug, Ray immediately began to deteriorate. They maintain that had they been instructed to watch for signs of suicidality, Ray would still be alive.

    Although it is largely unknown to the public, over the past 15 years, hundreds of SSRI-related lawsuits have been quietly settled out of court. The drug companies have gone to great lengths to avoid jury trials in order to keep the particulars of the lawsuits and the health risks associated with SSRIs hidden from public view.

    However, in recent years, the filing of lawsuits has picked up speed as more people become aware of the link between SSRIs and serious side effects, usually as a result of media attention focused on information uncovered in litigation. More often than not, the information verifies that the drug companies intentionally concealed their own negative studies showing the health risks associated with SSRI and their lack of efficacy.

    One FDA evaluation that surfaced as a result of litigation on the spontaneous post-marketing reports of "hostility" and "intentional injury" by people on Prozac, generated shortly before a 1991 FDA advisory committee meeting, compared SSRI suicidality to the antidepressant, trazodone, and found a 20-fold increase in reports of hostility and intentional injury in patients on Prozac.

    The lawsuit filed on behalf of Ray Badyna, specifically cites an article published in 2000, on a study funded in part by Prozac maker Eli Lilly, and Paxil maker SmithKlineBeecham, that found the incident of deliberate self-harm by patients taking SSRIs to be 5.5 times higher than persons taking tricyclic antidepressants.

    Recently a document became public that clearly shows the manipulation of study results in articles published on Pfizer's Zoloft (sertraline), by the medical communications agency, Current Medical Directions in 1998.

    The CMD published 6 articles on Zoloft use with children but all total, only 1 article mentions one suicidal act. However, according to Dr David Healy, one of the world's leading authorities on SSRIs, and author of "Let Them Eat Prozac," and "The Antidepressant Era," there were 6 suicidal acts.

    He says, the rate of suicidality in children taking Zoloft was in fact 9%, but Pfizer got away with not publishing these negative findings by only reporting side effects that occurred at a rate of 10% or higher.

    As far as the benefits of Zoloft, a study in the Journal of American Medical Association in April 2002, compared the effectiveness of Zoloft, St John's Wort, and a placebo and reported that placebo patients had the highest rate of remission of symptoms at 31.9%, and Zoloft's 24.8% rate of remission was barely better than the 23.9% of St John's Wort.

    The kinds of suicides that experts say are SSRI-induced are extremely violent, totally unexpected and impulsive. Notes are seldom left and many suicide attempt survivors recall a strange out of body like experience.

    For instance, 71-year-old Milton Cole, who was in good health and not depressed, went to a heart doctor with chest pains. After tests failed to reveal a heart problem, the doctor gave Mr Cole free samples of Prozac, supposedly to relieve the chest pain. Thirteen days later, his wife found him hanging from a beam in a back room of their shop, according to the November 3, 2003 Miami Herald.

    Dr Joseph Glenmullen, author of "Prozac Backlash," and "The Antidepressant Solution," explains that the difference between ordinary suicidality and SSRI induced suicidality can be distinguished because an activation syndrome usually accompanies SSRI suicidality, which includes akathisia and mania.

    Harvard trained psychiatrist, Dr Stefan Kruszewski, agrees and says, "Because the drugs cause predictable neurochemical changes in the central nervous system, SSRIs can also increase the risk of violence and aggressive acting out."

    On March 22, 2004, the FDA issued an Advisory warning that symptoms such as akathisia, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, hypomania, and mania had been reported in patients taking Prozac, Zoloft, Paxil, Luvox, Celexa, Lexapro, Wellbutrin, Effexor, Serzone and Remeron and recommended close observation of patients for worsening depression or emergence of suicidality.

    According to Attorney Braslow, at the time of this warning it was revealed that Forest had added a suicide warning on Celexa sold in Europe years earlier, but in the US there was no such warning on Lexapro or Celexa.

    "In addition," Mr Pogust reports, "the drug maker had previously conducted a number of European trials with both hospitalized and outpatient adolescents which showed Celexa to be no more effective than a placebo."

    In May 2005, the FDA published the alarming suicide rate for children taking SSRIs in a Public Health Alert that stated "1 in 50" kids on SSRIs become suicidal or have increased suicidality "DUE TO DRUG."

    The next month, another FDA Advisory warned that adult patients "should be watched closely for worsening of depression and for increased suicidal thinking or behavior."

    In addition to suicide, some of the most serious adverse events reported to be associated with SSRIs in recent years, are birth defects. Many studies have determined that SSRIs are harmful to the unborn fetus. In April 2006, a study in the American Journal of Obstetrics and Gynaecology, by Canadian researchers, found that SSRIs use during pregnancy doubled the mother's risk of delivering a stillborn infant and increased the risk of premature delivery, underweight babies, and seizures.

    These findings are important for doctors to know because according to a report by CDC researchers last year in Pediatrics, preterm birth is the leading cause of infant mortality in the US, accounting for at least a third of all deaths in 2002.

    The harms to the fetus reported include a withdrawal syndrome, requiring prolonged hospital stays, respiratory support and tube feeding and a 6-fold increase in the life-threatening lung disorder, persistent pulmonary hypertension, as well as serious heart birth defects that require open heart surgery to correct.

    In September 2005, studies conducted by Danish and US researchers found that the use of SSRIs in the first 3 months of pregnancy was linked to a 40% increased risk of birth defects such as cleft palate, and a 60% increase in cardiac defects. One study of 1,054 women who took SSRIs found they increased the risk of premature birth by 40%.

    As a result of the rising number birth defects found to be associated with SSRIs, drug companies are facing a slew of lawsuits. They are reportedly especially worried about birth defect information becoming public because medical experts estimate that tens of thousands of infants in the US have SSRI-related birth defects, with the blame largely unknown to the parents.

    Nearly 10 years ago, one of the harshest admonishments about the over-prescribing of SSRIs came in an Editorial in the October 20, 1997, issue of Time Magazine by Candace Pert, a professor at Georgetown University Medical Center at the time, as one of the two scientists who discovered the serotonin binding process, which stated in part:

    I am alarmed at the monster that Johns Hopkins neuroscientist Solomon Snyder and I created when we discovered the simple binding assay for drug receptors 25 years ago.

    Prozac and other antidepressant serotonin-receptor-active compounds may also cause cardiovascular problems in some susceptible people after long-term use, which has become common practice despite the lack of safety studies.

    The public is being misinformed about the precision of these selective serotonin-uptake inhibitors when the medical profession oversimplifies their action in the brain and ignores the body as if it exists merely to carry the head around!

    "In short," she warned, "these molecules of emotion regulate every aspect of our physiology."

    Dr Healy says SSRIs continue to be over-prescribed even as researchers are finding more and more adverse events and doctors need to fully explain these side effects before prescribing the drugs so patients can make an informed choice about taking them.

    Persons seeking more information on cases involving Celexa related suicides can contact the Pogust & Braslow law firm at 610-941-4204, or

    Evelyn Pringle

    (This article is part of a series covering litigation involving the pharmaceutical industry and is sponsored by the Pogust & Braslow, LLC law firm)


    Evelyn Pringle is a columnist for OpEd News and investigative journalist focused on exposing corruption in government and corporate America.

    Contact Author

    Contact Editor

    View Other Articles by Author


    Bookmark this page: (what's this?)

    NETSCAPE      DIGG THIS      NEWSVINE      DEl.ICIO.US      Looksmart Furl      My Web      Spurl      Tag!RawSugar      Shadows Tag!      Blink List     (More...)
    Comments: Expand   Shrink   Hide  

    Question Concerning SSRI Situation

    I noticed today that you have an article that pertains to a situation I am facing and I plan to use the article in handling the situation. I would appreciate any thoughts you may have concerning it or if you would rather not express an opinion, I would totally understand. Almost 2 years ago my Dad's urinary function was blocked by an enlarged prostate. My Dad is 85 years old and they didn't want to do surgery but ultimately they did and he is doing pretty well physically though he is still on Flomax for the condition. Because his weight was very low on admission to North Shore Hospital in Manhasset, New York, his doctor and his second wife, Jan,(who is a nurse there in Hospital Administration) had him put on 10 mg of Lexapro a day which as far as I know, he is still on. I am alarmed at the dangers of this drug particularly heart attack. I am planning to show him him the data on the dangerousness of Lexapro and SSRIs because his second wife said he had an irregular heartbeat and heart problems before being put on Lexapro (which to me is asking for disaster). They installed a Pacemaker in his chest but only after he had been put on the Lexapro. I want to show him the adverse data and see if he will agree to go see another Doctor to get a 2nd opinion on whether he should stay on the Lexapro or not because it is extremely dangerous, and look at if he could be safely gradually weaned off of it under supervision of a competent Doctor. My Dad's second wife, Jan, started screaming at me in a threatening manner when I once mentioned my concerns about my Dad taking Lexapro in the past. She told me not to say anything because he could have a heart attack and die (which is exactly what I think might happen to him if he is kept on the Lexapro). I don't feel I am violating any law about offering medical advice or acting as a doctor in showing my father the adverse data and asking him if he will agree to go for a second opinion regarding staying on the Lexapro. My Dad has told me he has given given his 2nd wife, Jan, legal control over his medical care. I feel if I challenge Jan and my Dad's doctor that they are arrogant enough to do almost anything to punish one who challenges their viewpoint. I worry about being arrested for abusing my Father by asking him to go for a 2nd opinion. Do you know of this ever happening? Any thoughts or suggestions in case that should happen? Again, if you would rather not express an opinion on this I would totally understand. Thanks for your emails and information and for these articles.

    by larryb (0 articles, 9 comments) on Friday, February 23, 2007 at 7:04:05 AM




    Tell A Friend


    Copyright OpEdNews, 2002-2007
    advertise here



      A Promise Kept - Part 3
      by Jan Baumgartner
      by Frosty Wooldridge
      Book Review - Mosaic Virus, by Carlos T. Mock, MD
      by Richard LaBonte
      When it is Time to Go - Part 2
      by Jan Baumgartner
      Solitary Confinement - Part 1
      by Jan Baumgartner
      Lost Conversations: Richmond shipyard's rich African-American history will boggle your mind!
      by Jane Stillwater
      Paul Laurence Dunbar Website Releases New Version Of Dialect Poem "An Ante-Bellum Sermon"
      by Rev. Bill McGinnis
      by Professor Emeritus Peter Bagnolo
      by Frosty Wooldridge
      Book Review: People Around Us; edited by Holly Lachowicz and Barbara Seyda
      by Larry Sakin
      Wining and Dining in South Africa's Cape Winelands:
      by Jan Baumgartner
      Snips From The "Enemy" Blogs
      by Gatto
      Adventures in Activism, Motherhood, and Marriage
      by Melinda Pillsbury-Foster
      Is there Death before Death?
      by W. Christopher Epler (Bill)
      by Allen L Roland
      BOOK REVIEWS: The Mosaic Virus
      by Tracy Baim and Ken Furtato
      The Upside of Flu
      by Hollis Polk
      by Frosty Wooldridge
      by Allen L Roland
      by Allen L Roland
      the staR
      by W. Christopher Epler
      The Zoom of Abandon
      by W. Christopher Epler